A bioassay for possible carcinogenicity of technical-grade @entity70299 was conducted using Fischer 344 @entity35 and B6C3F1 @entity19 . @entity70299 was administered in the feed, at either of two concentrations, to groups of 45 to 50 males and females of each species. The high and low time-weighted average concentrations of @entity70299 were 0.20 and 0.10 percent, respectively, for male and female @entity35 . For @entity19 , two dosage regimens (designated A and B) were used, but the time-weighted average concentrations were the same, 0.06 percent. For each species, 50 animals of each sex were placed on test as controls. The period of compound administration was 78 weeks for @entity35 followed by 26 to 28 additional weeks of observation, and 73 weeks for @entity19 followed by 24 to 25 additional weeks of observation. A statistically significant positive association between compound administration and mortality was established for the male and female dose A @entity19 . Dose A @entity19 did not survive sufficiently long to be at risk from late-developing @entity5 . Survival in all other groups was adequate. The incidence of @entity157 was statistically significant among dosed @entity35 of both sexes. @entity703 (the combined incidence of @entity4434 , tubular-cell @entity420 , and @entity420 ) were significantly increased among dosed male @entity35 . Administration of the compound was associated with a significant increase in the combined incidence of @entity157 and neoplastic liver nodules in female @entity19 . No other @entity5 occurred in statistically significant positive incidences in male or female @entity19 . @entity70299 demonstrated nephrotoxic properties in @entity19 of both sexes. Under the conditions of this bioassay, @entity70299 was carcinogenic in Fischer 344 @entity35 , inducing @entity157 in @entity35 of both sexes, and @entity703 in male @entity35 . The compound was carcinogenic in female B6C3F1 @entity19 , producing an increased combined incidence of @entity157 and neoplastic nodules.

Bioassay of XXXX for possible carcinogenicity (CAS No. 82-28-0).

@entity19 :: ('10090', 'Species') :: ['mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasms', 'tumors'] @entity70299 :: ('MESH:C034090', 'Chemical') :: ['1-amino-2-methylanthraquinone', '1-Amino-2-methylanthraquinone'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinomas'] @entity4434 :: ('MESH:D005198', 'Disease') :: ['tubular-celladenomas'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinomas NOS'] @entity703 :: ('MESH:D007680', 'Disease') :: ['kidney tumors', 'Kidney neoplasms']
@entity70299 :: (MESH:C034090,Chemical) :: ['1-amino-2-methylanthraquinone']
